bioRxivBiochemistryPreprint
Identification of an H-Ras nanocluster disrupting peptide
G. b. Manoharan, C. L. Steffen, K. Pavic, A. Yeste-Vazquez, M. Knuuttila, N. Arora, Y. Zhou, H. Harma, A. Gaigneaux, T. N. Grossmann, D. K. Abankwa
Abstract
The Ras-MAPK pathway is critical to regulate cell proliferation and differentiation. Its dysregulation is implicated in the onset and progression of numerous types of cancers. To be active, Ras proteins are membrane anchored and organized into nanoclusters, which realize high-fidelity signal transmission across the plasma membrane. Nanoclusters therefore represent potential drug targets. However, targetable protein components of signalling nanoclusters are poorly established. We previously proposed that the nanocluster scaffold galectin-1 (Gal1) enhances H-Ras nanoclustering by stabilizing stacked dimers of H-Ras and Raf via a direct interaction of dimeric Gal1 with the Ras binding domain (RBD) in particular of B-Raf. Here, we provide further supportive evidence for this model. We establish that the B-Raf preference emerges from divergent regions of the Raf RBDs that were proposed to interact with Gal1. We then identify the L5UR peptide, which disrupts this interaction by binding with low micromolar affinity to the B-Raf-RBD. Its 23-mer core fragment is thus sufficient to interfere with Gal1-enhanced H-Ras nanocluster, reduce MAPK-output and cell viability in HRAS-mutant cancer cell lines. Our data therefore suggest that the interface between Gal1 and the RBD of B-Raf can be targeted to disrupt Gal1-enhanced H-Ras nanoclustering. Collectively, our results support that Raf-proteins are integral components of active Ras nanoclusters.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Positive cooperativity between RAS-binding and cysteine-rich domains regulates RAF membrane binding kinetics via lateral rebinding
Andres Jimenez Salinas, Kesaria Tevdorashvili, … Young Kwang Lee·Nature CommunicationsPeer-reviewed·Feb 10, 2026
- Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling
S. Lim, N. Boyer, … A. W. Partridge·bioRxiv·Sep 11, 2021
- Kinetic Signatures of RAS-BRAF Engagement Reveal Isoform Selectivity, Oncogenic Amplification, and Mutation-Dependent Inhibitor Resistance
Sravani Malasani, Zhihong Wang·FEBS JournalPeer-reviewed·Oct 27, 2026
- Crystal structure reveals the full Ras:Raf interface and advances mechanistic understanding of Raf activation
- Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition
Ana Orive-Ramos, Bijaya Gaire, … Poulikos I. Poulikakos·Cancer DiscoveryPeer-reviewed·Sep 29, 2026
- Raf promotes dimerization of the Ras G-domain with increased allosteric connections
M. Packer, J. A. Parker, … C. Mattos·Proceedings of the National Academy of SciencesPeer-reviewed·Mar 9, 2021